Verastem Inc (VSTM) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Verastem Inc   (NASDAQ: VSTM)


Verastem Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Verastem Inc's ROI in the second quarter of 2026?
Verastem Inc recorded a cumulative net loss of $-203 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -139.63%.

Within the Healthcare sector 659 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2285 to 4125.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 52.65 % 107.18 % 98.76 % 43.27 % 4.72 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 128 161 174 117 146
Return On Investment (TTM) -139.63 % -129.7 % -157.11 % -224.45 % -175.14 %
VSTM's Overall Ranking # 4125 # 2285 # 3493 # 3877 # 3455
Seq. Investment Change TTM -2.93 % 12.17 % 24.11 % 12.96 % 31.75 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -203 -194 -209 -241 -167

VSTM Company Profile >> Back to VSTM Roi Comparisons >> See Annual VSTM Return On Investment



Return On Investment VSTM's Ranking
Within: No.
Industry # 298
Sector # 660
Overall # 4125

Return On Investment Statistics
High Average Low
-27.94 %
-79.37 %
-224.03 %
(Jun 30 2021)   (Sep 30 2025)



  News about Verastem Inc Return on Investment ROI

Verastem Oncologys Game-Changing Submission to FDA Paves the Way for Targeted Therapy in KRAS Mutant Low-Gra...

November 1, 2024

In a significant milestone for cancer treatment, Verastem Oncology (Nasdaq: VSTM) has announced the completion of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a groundbreaking combination therapy targeting recurrent KRAS mutant low-grade serous ovarian cancer. This submission underscores Verastem s commitment to addressing the urgent need for effective treatment options for patients afflicted by this challenging cancer type. The Therapeutic Duo: Avutometinib and Defactinib The combination therapy comprises two investigational agents: avutometinib, a novel oral RAF/MEK clamp, and defactinib, an oral selective FAK (focal adhesion kinase) inhibitor. Together, these compounds represent a potential multi-faceted approach to combat cancer pathways that are often resistant to conventional therapies. Avutometinib works by targeting the RAF/MEK signaling pathway, a crucial mechanism that drives tumor growth and progression in numerous cancers, including those characterized by KRAS mutations. Meanwhile, defactinib s role as a selective FAK inhibitor aims to disrupt cellular signaling pathways tied to cancer development and metastasis. By combining these two therapeutics, Verastem seeks to enhance the therapeutic effect and improve outcomes for patients suffering from this subtype of ovarian cancer.

Verastem Oncology Advances Precision Therapeutics with Completion of NDA for Avutometinib-Defactinib Combination in R...

October 31, 2024

: The biopharmaceutical landscape is witnessing significant advancements as precision medicine continues to shape cancer treatment paradigms. Verastem Oncology, a pioneering entity in this realm, recently announced the culmination of its rolling New Drug Application (NDA) for a novel therapeutic combination that promises to redefine treatment strategies for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). This article delves into the implications of this submission to the U.S. Food and Drug Administration (FDA) and evaluates Verastem s financial health as it navigates hematotropic challenges within the healthcare sector.The relentless pursuit of targeted therapies in oncology has underscored the importance of addressing unmet medical needs in niche cancer populations. One such condition recurrent KRAS mutant low-grade serous ovarian cancer remains a clinical conundrum with restricted therapeutic options. Verastem Oncology s latest achievement in completing the NDA for avutometinib plus defactinib heralds a potential breakthrough for patients afflicted by this formidable malignancy.





Financial Statements
Verastem Inc's II. Quarter Investments $ 128 Millions VSTM's Balance sheet
Verastem Inc's II. Quarter Income $ -35 Millions Quarterly VSTM's Income Statement
VSTM's Income by Division See VSTM's Income by Division


VSTM Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 174 71 102 72 88
Y / Y Investment Growth 146.83 % -30.94 % 42.08 % -18.1 % -34.63 %
Net Income in Millions -209 -131 -87 -74 -71
Y / Y Net Income Growth - - - - -
Annual Return On Investment -120.27 % -185.13 % -85.5 % -102.63 % -81.09 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VSTM's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VSTM's Competitors
Subscribers only: Roi for Verastem Inc's Suppliers
Subscribers only: Return On Investment for VSTM's Customers

Other Ratios
VSTM's Roa VSTM's Inventory Turnover Ratio VSTM's Growth Rates VSTM's Dividend Statistics
VSTM's Profitability Ratios VSTM's Asset Turnover Ratio VSTM's Dividend Growth
VSTM's Roe VSTM's Valuation Ratios VSTM's Financial Strength Ratios VSTM's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:14:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.